NCT02646358

Study of the Effect of Renal Impairment on the Pharmacokinetics of Vepoloxamer

A Phase 1, Open-Label, Non-Randomized Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Vepoloxamer in Subjects With Varying Degrees of Renal Impairment and Healthy Matched Control Subjects With Normal Renal Function

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 27 (actual)
• Sponsor: Mast Therapeutics, Inc. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Accepted

Summary

This is an open-label study designed to evaluate the effect of renal disease on the pharmacokinetics of vepoloxamer relative to the pharmacokinetics in healthy subjects with normal renal function.

Conditions

• Pharmacokinetics of Vepoloxamer
• Healthy Volunteers
• Renal Impaired

Interventions

Type	Name	Description
DRUG	Vepoloxamer

Timeline

• Start date: 2016-01-01
• Primary completion: 2016-11-01
• First posted: 2016-01-05
• Last updated: 2016-12-22

Locations

2 sites across 1 country: United States